http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 26 Feb 2026 08:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.</p> <p align="justify">A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QD2C0OwgZqGCsMIpqqD5-LsvVEo3AdhzOSUeoj94F1xfrZm2SPqYULiBezP47YWCElkyVyHyAtcPsyI_clNwZYK58o10lQNcAxu-JuEC91OCKOpaJ1vwpZFrMSIAoRaGvODLEk5ME683oCi6Ww6To-3GiXiZtx7TRa9pxpO_39TQ32Trq_c-R5V4DEUfUvuX" rel="nofollow" target="_blank">live</a> and there will be a replay for approximately 90-days following the presentation on the News &amp; Events section of http://www.streetinsider.com/Press+Releases/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html Thu, 26 Feb 2026 08:00:00 -0500 A.50100012 MIST O.07505859 O.07579093 http://www.streetinsider.com/Press+Releases/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.</p> <p align="justify">A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QD2C0OwgZqGCsMIpqqD5-LsvVEo3AdhzOSUeoj94F1xfrZm2SPqYULiBezP47YWCElkyVyHyAtcPsyI_clNwZYK58o10lQNcAxu-JuEC91OCKOpaJ1vwpZFrMSIAoRaGvODLEk5ME683oCi6Ww6To-3GiXiZtx7TRa9pxpO_39TQ32Trq_c-R5V4DEUfUvuX" rel="nofollow" target="_blank">live</a> and there will be a replay for approximately 90-days following the presentation on the News &amp; Events section of http://www.streetinsider.com/Press+Releases/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html Thu, 26 Feb 2026 08:00:00 -0500 A.50100012 MIST O.07505859 O.07579093 http://www.streetinsider.com/Press+Releases/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.</p> <p align="justify">A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QD2C0OwgZqGCsMIpqqD5-LsvVEo3AdhzOSUeoj94F1xfrZm2SPqYULiBezP47YWCElkyVyHyAtcPsyI_clNwZYK58o10lQNcAxu-JuEC91OCKOpaJ1vwpZFrMSIAoRaGvODLEk5ME683oCi6Ww6To-3GiXiZtx7TRa9pxpO_39TQ32Trq_c-R5V4DEUfUvuX" rel="nofollow" target="_blank">live</a> and there will be a replay for approximately 90-days following the presentation on the News &amp; Events section of http://www.streetinsider.com/Press+Releases/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html Thu, 26 Feb 2026 08:00:00 -0500 A.50100012 MIST O.07505859 O.07579093 http://www.streetinsider.com/Press+Releases/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.</p> <p align="justify">A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QD2C0OwgZqGCsMIpqqD5-LsvVEo3AdhzOSUeoj94F1xfrZm2SPqYULiBezP47YWCElkyVyHyAtcPsyI_clNwZYK58o10lQNcAxu-JuEC91OCKOpaJ1vwpZFrMSIAoRaGvODLEk5ME683oCi6Ww6To-3GiXiZtx7TRa9pxpO_39TQ32Trq_c-R5V4DEUfUvuX" rel="nofollow" target="_blank">live</a> and there will be a replay for approximately 90-days following the presentation on the News &amp; Events section of http://www.streetinsider.com/Press+Releases/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html Thu, 26 Feb 2026 08:00:00 -0500 A.50100012 MIST O.07505859 O.07579093 http://www.streetinsider.com/Globe+Newswire/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.</p> <p align="justify">A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QD2C0OwgZqGCsMIpqqD5-LsvVEo3AdhzOSUeoj94F1xfrZm2SPqYULiBezP47YWCElkyVyHyAtcPsyI_clNwZYK58o10lQNcAxu-JuEC91OCKOpaJ1vwpZFrMSIAoRaGvODLEk5ME683oCi6Ww6To-3GiXiZtx7TRa9pxpO_39TQ32Trq_c-R5V4DEUfUvuX" rel="nofollow" target="_blank">live</a> and there will be a replay for approximately 90-days following the presentation on the News &amp; Events section of http://www.streetinsider.com/Globe+Newswire/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html Thu, 26 Feb 2026 08:00:00 -0500 A.50100012 MIST O.07505859 O.07579093 http://www.streetinsider.com/Globe+Newswire/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.</p> <p align="justify">A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QD2C0OwgZqGCsMIpqqD5-LsvVEo3AdhzOSUeoj94F1xfrZm2SPqYULiBezP47YWCElkyVyHyAtcPsyI_clNwZYK58o10lQNcAxu-JuEC91OCKOpaJ1vwpZFrMSIAoRaGvODLEk5ME683oCi6Ww6To-3GiXiZtx7TRa9pxpO_39TQ32Trq_c-R5V4DEUfUvuX" rel="nofollow" target="_blank">live</a> and there will be a replay for approximately 90-days following the presentation on the News &amp; Events section of http://www.streetinsider.com/Globe+Newswire/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html Thu, 26 Feb 2026 08:00:00 -0500 A.50100012 MIST O.07505859 O.07579093 http://www.streetinsider.com/Globe+Newswire/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.</p> <p align="justify">A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QD2C0OwgZqGCsMIpqqD5-LsvVEo3AdhzOSUeoj94F1xfrZm2SPqYULiBezP47YWCElkyVyHyAtcPsyI_clNwZYK58o10lQNcAxu-JuEC91OCKOpaJ1vwpZFrMSIAoRaGvODLEk5ME683oCi6Ww6To-3GiXiZtx7TRa9pxpO_39TQ32Trq_c-R5V4DEUfUvuX" rel="nofollow" target="_blank">live</a> and there will be a replay for approximately 90-days following the presentation on the News &amp; Events section of http://www.streetinsider.com/Globe+Newswire/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html Thu, 26 Feb 2026 08:00:00 -0500 A.50100012 MIST O.07505859 O.07579093 http://www.streetinsider.com/Globe+Newswire/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.</p> <p align="justify">A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QD2C0OwgZqGCsMIpqqD5-LsvVEo3AdhzOSUeoj94F1xfrZm2SPqYULiBezP47YWCElkyVyHyAtcPsyI_clNwZYK58o10lQNcAxu-JuEC91OCKOpaJ1vwpZFrMSIAoRaGvODLEk5ME683oCi6Ww6To-3GiXiZtx7TRa9pxpO_39TQ32Trq_c-R5V4DEUfUvuX" rel="nofollow" target="_blank">live</a> and there will be a replay for approximately 90-days following the presentation on the News &amp; Events section of http://www.streetinsider.com/Globe+Newswire/Milestone%C2%AE+Pharmaceuticals+to+Present+at+the+TD+Cowen+46th+Annual+Health+Care+Conference/26064841.html Thu, 26 Feb 2026 08:00:00 -0500 A.50100012 MIST O.07505859 O.07579093 http://www.streetinsider.com/Corporate+News/Milestone+Pharmaceuticals+names+David+Sandoval+general+counsel/25971738.html <p>Milestone Pharmaceuticals Inc. (NASDAQ: MIST) appointed David Sandoval as General Counsel and Chief Compliance Officer, the company announced Feb. 10. The appointment coincides with Milestone's launch of CARDAMYST, a nasal spray approved by the U.S. Food and Drug Administration on Dec. 12, 2025, for treating acute episodes of paroxysmal supraventricular tachycardia in adults.</p><p>Sandoval brings over 15 years of experience in legal and compliance roles across the life sciences sector, with focus on late-stage development, regulatory approval and product commercialization. He will serve on Milestone's executive leadership team and provide legal counsel across contracts, finance, investor relations, business development, intellectual property http://www.streetinsider.com/Corporate+News/Milestone+Pharmaceuticals+names+David+Sandoval+general+counsel/25971738.html Tue, 10 Feb 2026 08:03:04 -0500 MIST http://www.streetinsider.com/Management+Changes/Milestone+Pharmaceuticals+names+David+Sandoval+general+counsel/25971738.html <p>Milestone Pharmaceuticals Inc. (NASDAQ: MIST) appointed David Sandoval as General Counsel and Chief Compliance Officer, the company announced Feb. 10. The appointment coincides with Milestone's launch of CARDAMYST, a nasal spray approved by the U.S. Food and Drug Administration on Dec. 12, 2025, for treating acute episodes of paroxysmal supraventricular tachycardia in adults.</p><p>Sandoval brings over 15 years of experience in legal and compliance roles across the life sciences sector, with focus on late-stage development, regulatory approval and product commercialization. He will serve on Milestone's executive leadership team and provide legal counsel across contracts, finance, investor relations, business development, intellectual property http://www.streetinsider.com/Management+Changes/Milestone+Pharmaceuticals+names+David+Sandoval+general+counsel/25971738.html Tue, 10 Feb 2026 08:03:04 -0500 MIST http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Press+Releases/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265 http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html <p align="justify">MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Kn5t0vjek8uUNJ4zBfdcaEFsTHZMfzSoKK2Gb0AHYp8otOeNaaM-UQF-b4M0lKkGmmHRZftmLsLB84E1YyCFy_1sCz57QgQ9jm2bFOYB-gbmOZgqH_2i0xIXKd0ShwjUxBK0FiROiEPmcjCHiHodk7k9O2xgCYrogL4pGHJHhPQ966MSE_NL_1pCdJ39_SRJZJUNxzNKxVKQU2og-QrYSc998WgA3o2lzs20ZAE8rrFjyfwpEesyULBpzhFCXDKZ5ZW0Dom4c_Z8Ooe99KE-Fdet1uw6sAPhnn6PfDCqPhg=" rel="nofollow" target="_blank">Milestone launches CARDAMYST™ (etripamil) nasal spray</a>, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=E7M1sRk3NIX1hfriX-b72DBzKt06qjUs4Fc5Bosq2T6R1HNpTU4wy6B_xXIlwfWRqqDddE7Ovnsft758u57MFQKnGP2Apfldmf0R_WF4ZLetR7sL2xHBFccLcF2hpVXm6ySRU_k02VHq5NJiAIL61xZAfdJPjWQGeOdQYYJ3OPBhCWvpQPc0PAPM28oBbxLnG-tcXqSzE2ZOToHyYq6axTfVr3GnvELYouPw2bWpwmVbEb3u-1zL1vAsJRVwXpuEtey-scEok_CQ5QOTuLYJ8eegJc1ciFwZ8Em19estmHdxuEVQ5XWqYBXre5CDxhju8jd3K1KQmDthgKpzRIrtig==" rel="nofollow" target="_blank">approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025</a>. He will serve as a member of Milestone’s executive leadership team and will provide http://www.streetinsider.com/Globe+Newswire/Milestone+Pharmaceuticals+Appoints+David+Sandoval+as+General+Counsel+and+Chief+Compliance+Officer/25971676.html Tue, 10 Feb 2026 08:00:00 -0500 A.00350660 A.11820776 A.31757664 A.39900073 A.40557829 MIST O.00093063 O.02048399 O.06141993 O.07505859 O.29384338 O.41770265